Renal cancer steroid receptors: biochemical basis for endocrine therapy.
Estradiol receptor (ER) and progesterone receptor (PR), found in experimental renal cancer as well as in normal human kidney and in human renal cell carcinoma (RCC), have been measured in 27 RCCs from patients submitted to surgery and endocrine therapy in an attempt to predict the response to progestational therapy. Of these 27 tumors 59% were positive for ER and 59% for PR; 37% were positive and 19% negative for both ER and PR. The follow-up of 23 patients showed that progestational therapy, started in 18 patients, has given favorable results in 14 patients and negative results in 3 patients with ER-PR- renal cancer. Antiestrogenic therapy, started soon after nephrectomy in 1 patient with ER+PR- renal cancer and lung metastases, failed since the patient died 8 months after surgery.
D000230:Adenocarcinoma / Q000032:analysis* / Q000188:drug therapy / Q000601:surgery; D000368:Aged; D004958:Estradiol / Q000378:metabolism; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000032:analysis* / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use; D008875:Middle Aged; D009392:Nephrectomy; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D004958:Estradiol; D008525:Medroxyprogesterone